title: Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus Infection.
abstract: Chronic hepatitis delta virus infection (CHD) is a condition arising from super-infection of hepatitis B virus (HBV)-infected patients, resulting in a more rapid advance in liver pathology and hepatocellular carcinoma than is observed for HBV mono-infection. Although hepatitis delta virus (HDV) is structurally simple, its life cycle involves the complex participation of host enzymes, HBV-derived surface antigen (HBsAg), and HDV-auto-ribozyme and hepatitis delta antigen (HDAg) activities. Unsatisfactory clinical trial results with interferon-based therapies are motivating researchers to adjust and redirect the approach to CHD drug development. This new effort will likely require additional structural and functional studies of the viral and cellular/host components involved in the HDV replication cycle. This review highlights recent work aimed at new drug interventions for CHD, with interpretation of key pre-clinical- and clinical trial outcomes and a discussion of promising new technological approaches to antiviral drug design.
authors: Huron Peak Ave., Superior, CO 80027, USA. Zhiminguogg@gmail.com.
authors: Zhimin
authors: Z
authors: Guo
authors: Allevagen, LLC, 4105 Perry St., Denver, CO 80212, USA. Thomas.King@allevagen.com.
authors: Thomas
authors: T
authors: King
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015195:Drug Design; D006515:Hepatitis B virus / Q000187:drug effects; D019701:Hepatitis D, Chronic / Q000188:drug therapy* / Q000821:virology; D003698:Hepatitis Delta Virus / Q000187:drug effects* / Q000502:physiology; D054884:Host-Pathogen Interactions / Q000187:drug effects*; D006801:Humans; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents
keywords: HBV; HDV; HIV; clinical; deltavirus; hepatitis; therapeutic; trial